[Enigma Biomedical USA (Business Wire)] Enigma Biomedical USA announced the US FDA approval of TAUKLARIFY™, a radiodiagnostic agent indicated for positron emission tomography of the brain in adults with cognitive impairment who are being evaluated for Alzheimer’s disease to identify patients with tau neurofibrillary tangle pathology.